维普期刊资源整合服务平台（V6.5）

319篇 您的检索式：作者名="NAUCK MA"

选中清除导出查看参考文献查看引证文献引用追踪共16页首页上一页第1页下一页末页 /16 跳转

	题名	作者	年代	出处	被引量
1	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemie control and lowers body weight in subjects with type 2 diabetes显示文摘	Nauck MA Hompesch M Filipczak R	2006	Exp Clin Endocrinol Diabetes2006，114，8：	1
2	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study显示文摘	Nauck MA Duran S Kim D	2007	Diabetologia2007，50，2：	1
3	Unraveling the science of incretin biology显示文摘	Nauck MA	2009	Am JMed2009，122，6：	1
4	A comparison of twicedaily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study 显示文摘	Nauck MA Duran S Kim D	2007	Diabetologia2007，50，2：	1
5	Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes显示文摘	Nauck MA Meier JJ	2005	Regul Pept2005，124，：	1
6	Additive insulinotropie effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon- like peptide-l(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations显示文摘	Nauck MA Barrels E Orskov C	1993	J Clin Endocrinol Metab1993，76，4：	1
7	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 irthibitors in type 2 diabetes 显示文摘	Drucker D J Nauck MA	2006	Lancet2006，368，9548：	1
8	The incretin system: gluca- gon-like peptide-1 receptor agonists and dipeptidyl peptidase-d inhibitors in type 2 diabetes 显示文摘	Drucker DJ Nauck MA	2006	Lancet2006，368，9548：	1
9	The incretin system:glucagon-like peptide-1 receptor agonists and didpeptidyl peptidase4 inhibitors in type 2 diabetes 显示文摘	Drucker DJ Nauck MA	2006	Lancet2006，368，9548：	1
10	The incretin system : glucagon-like pep-tide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors intype 2 diabetes显示文摘	Drucker DJ Nauck MA	2006	Lancet2006，368，9548：	1
11	Preserved incretin activity of lucagons-like peptide[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus显示文摘	Nauck MA Heimesaat MM Orskov C		0，，：	1
12	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 dia- betes显示文摘	Drucker D J Nauck MA	2006	Lancet2006，368，9548：	1
13	Incretins and their analogues as new antidiabetic drugs 显示文摘	Nauck MA Meier J J Creutzeldt W	2003	Drug News Perspect2003，16，7：	1
14	Do GLP-1 - based therapies increase cancer risk?显示文摘	Nauck MA Friedrich N	2013	Diabetes Care2013，36，2：	1
15	Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans显示文摘	Nauck MA Niedereichholz U Ettler R	1997	Am J Physiol (Endocrinol Metab)1997，273，5：	1
16	Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide显示文摘	Deacon CF Nauck MA Meier J		0，，：	1
17	Incretins and the development of type 2 diabetes 显示文摘	Meier JJ Nauck MA	2006	Curr Diab Rep2006，6，3：	1
18	Treatment with the humanonce-weekly glucagon-like peptide-1 analog taspoglutide in combi-nation with metformin improves glycemic control and lowers bodyweight in patients with type 2 diabetes inadequately controlled withmetformin alone:a double-blind placebo-controlled study显示文摘	Nauck MA Ratner RE Kaptiza C	2009	Diabetes Care2009，32，7：	1
19	Effects of glucagon-like peptide 1 on counter regulatory hormone responses,cognitive functions,and insulin secretion during hyperinsulinemic,stepped hypoglycemic clamp experiments in healthy volunteers显示文摘	Nauck MA Heimesaat MM Behle K	2002	J Clin Endocrinol Metab2002，87，3：	1
20	Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes 显示文摘	Maggs D MacDonald I Nauck MA	2008	Dia- betes Obes Metab2008，10，：	1

返回顶部每页显示：

共16页首页上一页第1页下一页末页 /16 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示